Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era – DocWire News

This article was originally published here

Curr Cardiol Rep. 2021 May 7;23(6):69. doi: 10.1007/s11886-021-01501-7.

ABSTRACT

PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic.

RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence suggesting that COVID-19 increases the risk of acute coronary syndromes (ACS). We propose characterizing ACS patients into 3 distinct categories to better assist in appropriate triage and management: critically ill patients, non-critically ill ST elevation myocardial infarction (STEMI) patients, and non-critically ill non-ST elevation myocardial infarction (NSTEMI)/unstable angina (UA) patients. We thoroughly review treatments strategies, management considerations, and current consensus statements for the care of COVID-19 patients with ACS. As we continue to gain more experience with management of COVID-19 in ACS patients and as health-care workers and patients continue to get vaccinated, we must continue to adapt our strategies to treat this high-risk group of patients.

PMID:33961122 | DOI:10.1007/s11886-021-01501-7

See the rest here:
Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era - DocWire News